Skip to content
value.today

Teleflex Incorporated: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -10.6% a year, held within -10% to 25% (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $5.5 B means free cash flow growing 23.7% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew -10.6% a year over the last three years.

Cash-flow value of the shares
$-1.6 B
-128% against the market value
Value of the whole business
$702 M
before net debt
Value from after year 10
31%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-15%-12.5%-10%-7.5%-5%
8.15%-130%-128%-125%-122%-118%
9.15%-131%-129%-127%-124%-121%
10.15%-132%-130%-128%-126%-123%
11.15%-132%-131%-129%-127%-125%
12.15%-133%-132%-130%-129%-126%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Price to salesPrice to sales of Medical Instruments: $3.7 B to $13.7 B, median $7.3 BPrice to bookPrice to book of Medical Instruments: $6.6 B to $21.1 B, median $14.0 B$0 M$5.7 B$11.4 B$17.1 B$22.7 BMarket value $5.5 B

Your own DCF model

A full discounted-cash-flow model of Teleflex Incorporated, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Teleflex Incorporated's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Teleflex IncorporatedApplied toValue (25th to 75th)Companies
Price to sales1.9× / 3.7× / 6.9×2.4×revenue $2.0 B$3.7 B to $13.7 B22
Price to book2.1× / 4.5× / 6.7×1.8×book equity $3.1 B$6.6 B to $21.1 B22

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Teleflex Incorporated's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

30.6×

Now below its median of 35.6×, in the bottom quarter of its range; range 24.1× to 93.5× over 18 months.

0×23×47×70×93×202020212022202320242025P/E 31×Median 36×

Price to sales

2.5×

Now below its median of 3.1×, in the bottom quarter of its range; range 2.3× to 7.4× over 27 months.

0×2×4×6×7×2020202120222023202420252026Price to sales 2×Median 3×

Price to book

1.8×

Now close to its median of 1.7×; range 1.1× to 6.9× over 30 months.

0×2×3×5×7×2020202120222023202420252026Price to book 2×Median 2×

as of Oct 28, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 28, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$2.0 B$-906 M$97 M$95 M$1 M$2.3 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$1.7 B$70 M$302 M$90 M$211 M$1.4 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$1.7 B$356 M$206 M$46 M$160 M$1.6 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$2.8 B$363 M$343 M$79 M$264 M$1.4 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$2.8 B$485 M$652 M$72 M$581 M$1.4 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$2.5 B$335 M$437 M$91 M$346 M$2.1 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $5.5 B on Oct 28, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.